CYP3A4*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults.

The CYP3A4*22 (c.522-191 C>T; rs35599367) single nucleotide polymorphism has been associated with lower CYP3A4 mRNA expression and activity. We investigated the association of CYP3A4*22 with the pharmacokinetics of lopinavir through a population pharmacokinetic approach. The minor allele frequency for CYP3A4*22 was 0.035, and seven of 375 patients had a combination of CYP3A4*22 and SLCO1B1 521T>C alleles. Lack of information on the ethnicity in this cohort should be considered as a limitation. However, in the final model, the population clearance was 5.9 l/h and patients with CYP3A4*22/*22 had 53% (P=0.023) lower clearance compared with noncarriers. In addition, the combined effect of CYP3A4*22 with SLCO1B1 521T>C (previously shown to be associated with lopinavir plasma concentration) was analysed. We observed a 2.3-fold higher lopinavir trough concentration (Ctrough) in individuals with CYP3A4*22/*22, a 1.8-fold higher Ctrough with SLCO1B1 521CC and a 9.7-fold higher Ctrough in individuals homozygous for both single nucleotide polymorphisms, compared with noncarriers. A simulated dose-reduction scenario showed that 200/100 mg lopinavir/ritonavir was adequate to achieve therapeutic concentration in individuals with CYP3A4*22/*22 alone or in combination with SLCO1B1 521CC. These data further our understanding of the genetic basis for variability in the pharmacokinetics of lopinavir.

[1]  V. Haufroid,et al.  Impact of CYP3A4*22 Allele on Tacrolimus Pharmacokinetics in Early Period After Renal Transplantation: Toward Updated Genotype-Based Dosage Guidelines , 2013, Therapeutic drug monitoring.

[2]  G. Koren,et al.  CYP3A4*22 and CYP3A combined genotypes both correlate with tacrolimus disposition in pediatric heart transplant recipients. , 2013, Pharmacogenomics.

[3]  D. Hesselink,et al.  The CYP3A4*22 allele affects the predictive value of a pharmacogenetic algorithm predicting tacrolimus predose concentrations. , 2013, British journal of clinical pharmacology.

[4]  U. Zanger,et al.  Pharmacogenomics of Cytochrome P450 3A4: Recent Progress Toward the “Missing Heritability” Problem , 2013, Front. Genet..

[5]  V. Haufroid,et al.  CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin. , 2013, Pharmacogenomics.

[6]  Laurent Gil,et al.  Ensembl 2013 , 2012, Nucleic Acids Res..

[7]  M. Youle,et al.  Estimation of the Effect of Slco1B1 Polymorphisms on Lopinavir Plasma Concentration in HIV-Infected Adults , 2012, Antiviral therapy.

[8]  Jie Lu,et al.  CPY3A4-Mediated Lopinavir Bioactivation and Its Inhibition by Ritonavir , 2012, Drug Metabolism and Disposition.

[9]  V. Haufroid,et al.  Functional defect caused by the 4544G>A SNP in ABCC2: potential impact for drug cellular disposition , 2011, Pharmacogenetics and genomics.

[10]  A. Hofman,et al.  Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in The Rotterdam Study , 2011, Pharmacogenetics and genomics.

[11]  V. Haufroid,et al.  A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. , 2011, Clinical chemistry.

[12]  V. Haufroid,et al.  Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients. , 2011, Pharmacogenomics.

[13]  W. Sadee,et al.  Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs , 2011, The Pharmacogenomics Journal.

[14]  J. Absalon,et al.  Gastrointestinal tolerability and quality of life in antiretroviral-naïve HIV-1-infected patients: data from the CASTLE study , 2010, AIDS care.

[15]  J. Absalon,et al.  Once-Daily Atazanavir/Ritonavir Compared With Twice-Daily Lopinavir/Ritonavir, Each in Combination With Tenofovir and Emtricitabine, for Management of Antiretroviral-Naive HIV-1–Infected Patients: 96-Week Efficacy and Safety Results of the CASTLE Study , 2010, Journal of acquired immune deficiency syndromes.

[16]  S. Khoo,et al.  HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms , 2010, Pharmacogenetics and genomics.

[17]  Matthias Cavassini,et al.  ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir , 2010, Pharmacogenetics and genomics.

[18]  V. Haufroid,et al.  Association between ABCC2 polymorphism and lopinavir accumulation in peripheral blood mononuclear cells of HIV-infected patients. , 2009, Pharmacogenomics.

[19]  G. Morse,et al.  Pharmacogenomics of CYP3A: considerations for HIV treatment. , 2009, Pharmacogenomics.

[20]  S. Khoo,et al.  Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-->T) with reduced concentrations of unboosted atazanavir. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  Danielson Pb,et al.  The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. , 2002 .

[22]  A. Paterson,et al.  Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. , 2000, Pharmacogenetics.

[23]  P. Vouros,et al.  Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[24]  H. Yamazaki,et al.  Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.

[25]  B. Dvorchik,et al.  Genetic variation in rates of antipyrine metabolite formation: a study in uninduced twins. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[26]  V. Haufroid,et al.  CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy. , 2013, Pharmacogenomics.

[27]  G. Suarez-Kurtz,et al.  The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men. , 2010, British journal of clinical pharmacology.

[28]  J. Schapiro,et al.  Updated guideline to perform therapeutic drug monitoring for antiretroviral agents. , 2006 .

[29]  P. Danielson,et al.  The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. , 2002, Current drug metabolism.